In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session.

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

Abbott also is a buy for its dividend strength. As a Dividend King it's raised its dividend for more than 50 consecutive ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

Female mammals typically carry two X chromosomes — one from each parent — and a new study suggests that the maternal X is ...